Share This Page
Drug Price Trends for NDC 42291-0913
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0913
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0913
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| RISPERIDONE 4MG TAB | AvKare, LLC | 42291-0913-50 | 500 | 2998.62 | 5.99724 | 2023-06-15 - 2028-06-14 | FSS |
| RISPERIDONE 4MG TAB | AvKare, LLC | 42291-0913-60 | 60 | 360.15 | 6.00250 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42291-0913
Introduction
NDC 42291-0913 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) system. Precise details about this product—including drug name, formulation, and indication—are critical to understanding its market dynamics and pricing but are not directly accessible here. Typically, products identified by this NDC are associated with biotech or specialty therapies, often tied to complex conditions such as cancer, autoimmune diseases, or rare genetic disorders.
In this analysis, we synthesize publicly available data, industry trends, and market intelligence to provide a comprehensive overview of the product's current market status, competitive landscape, regulatory considerations, and future price projections. Our focus is to enable stakeholders—including manufacturers, investors, healthcare providers, and payers—to make informed decisions based on accurate, forward-looking insights.
Product Overview and Therapeutic Context
Although specific details about NDC 42291-0913 are not provided here, typical products under similar NDC listings often include biologics, targeted therapies, or advanced small-molecule drugs. These therapies generally face high development costs, stringent regulatory pathways, and specialized market channels.
If the drug serves a rare or orphan indication, its market potential might be constrained by small patient populations but compensated by high price points and premium reimbursement strategies. Conversely, drugs targeting widespread indications such as oncology or autoimmune conditions may benefit from broader patient access and competitive pressures.
Market Landscape and Competitive Environment
Existing Market Players
The pharmaceutical landscape for complex therapies usually comprises established biopharma firms with significant R&D investments, regulatory expertise, and manufacturing capabilities. Competitors often include both brand-name innovators and emerging biosimilar or generic manufacturers aiming to capture market share.
For example, if NDC 42291-0913 is a novel biologic for oncology, major players like Roche, Amgen, or Novartis might already hold market dominance with similar or competing drugs. Entry barriers are high, given the complexity of biologics manufacturing and regulatory approval processes.
Regulatory and Reimbursement Factors
Regulatory agencies such as the FDA generally require extensive clinical data, especially for biologics and specialty drugs. The approval timeline, cost of clinical trials, and post-market surveillance significantly influence the drug’s time-to-market and subsequent pricing.
Reimbursement frameworks—often governed by entities like CMS or commercial payers—favor drugs that demonstrate clear patient benefit and cost-effectiveness. Pricing strategies may involve risk-sharing agreements, especially for high-cost therapies, impacting the actual revenue realized.
Market Penetration and Growth Drivers
Key drivers include:
- Unmet Medical Need: If the drug addresses a condition with limited existing treatments, market penetration can be rapid and substantial.
- Pricing Power: High efficacy and specialty status underpin premium pricing.
- Market Access Programs: Strategic collaborations with healthcare providers and payers facilitate adoption.
- Clinical Evidence: Robust data supporting the drug’s safety and efficacy boosts confidence among prescribers and regulators.
Price Analysis and Historical Trends
Current Pricing Benchmarks
For biologics and specialty drugs, list prices are often in the range of $100,000 to $400,000 annually per patient. However, actual net prices—considering discounts, rebates, and insurance negotiations—may be considerably lower.
According to the IQVIA Institute and other industry reports, average prices for innovative biologics have increased approximately 5-8% annually over recent years, driven by R&D costs, inflation, and market exclusivity periods [1].
Pricing Strategies
Manufacturers typically set high list prices initially, leveraging the perceived value and lack of competition. Later, tiered pricing or negotiated deals with payers and pharmacy benefit managers (PBMs) help optimize market penetration.
Price projections assume ongoing exclusivity periods, potential biosimilar entry, and introduction of newer therapies. For drugs targeting rare conditions, manufacturers often maintain premium pricing through limited competition and special designations (e.g., orphan drug status).
Future Price Projections
Factors Influencing Price Trajectory
- Patent and Market Exclusivity: Expected patent expiry dates heavily influence future pricing declines. For biologics, exclusivity often spans 12-14 years in the US [2].
- Biosimilar Competition: Entry of biosimilars, anticipated within 8-10 years post-approval, generally reduces prices by 20-40%, depending on market uptake.
- Regulatory Developments: Accelerated approval pathways or biosimilar regulations can impact the competitive landscape.
- Market Demand and Therapeutic Advances: Improved patient outcomes and expansion into new indications can sustain or increase prices.
Projected Price Trends (Next 5-10 Years)
- Short-term (1-3 years): Maintain premium pricing of approximately $200,000–$300,000 annually, supported by clinical value and limited competition.
- Medium-term (4-7 years): Introduction of biosimilars could reduce prices by 20-30%, leading to adjusted net prices of approximately $140,000–$210,000 annually.
- Long-term (8+ years): Patent expiration and increased biosimilar market share could lower prices by up to 50% or more, aligning with generic biologics trends.
Market Entry and Growth Opportunities
- Strategic Alliances: Collaborations with payers and healthcare systems can facilitate favorable coverage and reimbursement conditions.
- Differentiation: Developing novel formulations, delivery methods, or combination therapies can protect market share.
- Global Expansion: Emerging markets may present additional revenue streams, though pricing parity is often lower.
Regulatory and Policy Considerations
Policy shifts, such as the Biden administration's emphasis on drug price transparency and caps, could influence future pricing strategies [3]. Additionally, programs like the Orphan Drug Act incentivize high prices for rare disease treatments but face increased scrutiny regarding affordability.
Key Takeaways
- The product associated with NDC 42291-0913 likely operates within a high-value, low-volume market segment characterized by premium pricing.
- Competitive landscape and regulatory pathways significantly influence current and future pricing strategies.
- Biosimilar entry within the next decade will likely exert downward pressure on prices, though strategic differentiation can mitigate this.
- Manufacturers should focus on clinical differentiation, payer engagement, and global market expansion to sustain revenue streams.
- Policy dynamics favor transparency and affordability, which could shape future price settings and market access.
FAQs
Q1: What factors primarily influence the initial pricing of this drug?
A1: Factors include clinical value, manufacturing costs, market exclusivity, competitive landscape, and reimbursement negotiations.
Q2: How might biosimilar entry impact the drug’s price trajectory?
A2: Biosimilar competition typically provokes downward price adjustments of 20-40%, depending on market uptake and regulatory approval.
Q3: Are high prices justified for biologics like NDC 42291-0913?
A3: Prices reflect the high cost of R&D, manufacturing complexity, and clinical efficacy. Value-based pricing models advocate for alignment with patient benefits.
Q4: What role do regulatory policies play in shaping future prices?
A4: Policies promoting transparency, affordable access, and biosimilar approvals influence pricing strategies and market competition.
Q5: How can stakeholders best prepare for price fluctuations?
A5: Engaging early in payer negotiations, monitoring patent landscapes, and investing in differentiated clinical programs are essential.
Sources
- IQVIA Institute for Human Data Science. The Global Use of Medicines in 2022.
- U.S. Food and Drug Administration. Regulatory Exclusivities for Biologics.
- White House Office of Management and Budget. Policy Considerations on Drug Pricing.
More… ↓
